A study in The BMJ showed that diabetes patients who took SGLT2 inhibitors, such as canagliflozin, dapagliflozin and empagliflozin, were at a twofold higher risk of lower limb amputation and diabetic ketoacidosis, compared with users of GLP-1 receptor agonists. Researchers analyzed data on 34,426 diabetes patients from Sweden and Denmark and noted that, based on their findings, patients at high amputation risk "might be monitored more closely if SGLT2 inhibitors are used, and the risk of this adverse event may be considered when deciding on which drugs to use," said lead researcher Dr. Peter Ueda.
SGLT2 inhibitors tied to increased amputation risk in diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.